Trial · NCT06142396
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
NCT06142396, Early phase 1, Recruiting, Augusta University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure. Trials, record NCT06142396. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06142396
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
- NCT number
- NCT06142396
- Status
- Recruiting
- Phases
- Early phase 1
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Augusta University
- Conditions
- Multiple Myeloma, Renal Failure
- Interventions
- Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
- First posted
- 2023-11-21
- Last updated
- 2026-03-12
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | VGPR | 4 months | Very good partial response rate (VGPR) or better after 4 cycles of Dara-CyBorD |
| Primary | Renal Response Rate (RRR) | 4 months | Renal response rate (RRR, defined as \> 30% improvement in creatinine clearance - CrCl from baseline at the point of study entry) after 4 cycles of Dara-CyBorD |
| Secondary | Overall response rate (ORR) | 4 months | Overall response rate (ORR) after 4 cycles of Dara-CyBorD |
| Secondary | VGPR, CR, & MRD | 4 months | Proportion of patients achieving VGPR, CR, and measurable residual disease negativity \<10-5 (MRD-), if applicable, after 4 cycles of Dara-CyBorD |
| Secondary | Duration of response (DOR) | 2 years | Duration of response (DOR), defined from the date response achieved to the date of disease relapse |
| Secondary | Time to renal response | 2 years | Time to renal response, defined as the number of days from starting treatment to \>30% improvement of CrCl from CrCl at study entry or achieving dialysis independence |
| Secondary | Dialysis independence | 4 months | Proportion of participants who achieved dialysis independence after four cycles of Dara-CyBorD |
| Secondary | autologous stem cell transplantation (ASCT) | 4 months | Proportion of patients undergoing autologous stem cell transplantation (ASCT) after 4 cycles of Dara-CyBorD induction |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06142396
GET https://conductscience.org/api/trials/v1/NCT06142396/registered